[{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"VYNE Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Topical Foam","sponsorNew":"Journey Medical Corporation \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Maruho"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ SWK Holdings"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Journey Medical Corporation \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Journey Medical Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : FDA has approved Emrosi (minocycline hydrochloride extended release capsules), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.

Product Name : Emrosi

Product Type : Small molecule

Upfront Cash : Not Applicable

November 04, 2024

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of antibacterial activity. It is being evaluated for treating papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

March 18, 2024

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Dr. Reddy\'s Laboratories

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The funding will support anticipated expenses for DFD-29 (minocycline hydrochloride), developed for treating rosacea, including an upcoming NDA submission and preparation for its potential launch.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Undisclosed

January 02, 2024

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : SWK Holdings

Deal Size : Undisclosed

Deal Type : Financing

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosace...

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

December 05, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Dr. Reddy\'s Laboratories

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of ...

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

October 20, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

July 11, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

July 03, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Dr. Reddy\'s Laboratories

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline hydrochloride modified release capsules) was developed using Multiple Unit Pellet System technology, which is being investigated for the treatment of papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

June 13, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Dr. Reddy\'s Laboratories

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

March 16, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : DFD-29 (minocycline) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.

Product Name : DFD-29

Product Type : Small molecule

Upfront Cash : Not Applicable

January 10, 2023

Lead Product(s) : Minocycline Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank